Clinical Trial Results Home

Antiplatelet Parenteral GPiibiiia Inhibitors

Contents
Abciximab (ReoPro) Slides
      -Summary
      -Trials

Aggrastat (Tirofiban) Slides
      -Summary
      -Trials

Eptifibatide (Integrilin) Slides
      -Summary
      -Trials

Abciximab (ReoPro) Slides

Summary

Abciximab Clinical Trial Overview

      -Use of ReoPro in Acute Coronary Syndrome



Trials

AIDA STEMI MRI: Cardiac MRI Substudy from a Prospective, Randomized Trial of Intracoronary Abciximab in Patients with ST-Segment Elevation Myocardial Infarction

      -Study Overview by Dr. Holger Thiele (TCT 2012) 


CAPTURE: C7E3 Fab Anti-Platelet Therapy in Unstable REfractory Angina

      -Trial Overview

 

CICERO: Intracoronary Versus Intravenous Abciximab in ST-Elevation Myocardial Infarction

      -Trial Results in Patients Undergoing Primary Percutaneous Coronary Intervention with Thrombus Aspiration by Dr. Youlan L. Gu (AHA 2010)

 

CRYSTAL AMI: Intracoronary Site-Specific Abciximab Compared to Intravenous Abciximab in Patients with Acute Myocardial Infarction Undergoing Primary Angioplasy

       -A Prospective Randomized Trial of Intracoronary Site-Specific Abciximab Compared to Intravenous Abciximab in Patients with Acute Myocardial Infarction Undergoing Primary Angioplasy by Dr. Rajesh M. Dav (TCT 2010)

       -Pilot Trial Results by Dr. Saihari Sadanandan (C3 Complex Intervention Meeting 2011)

E3C: EPIC, EPILOG, EPISTENT, CAPTURE

      -Long-Term Mortality Follow-Up

EASY: EArly Discharge after Transradial Stenting of CoronarY Arteries

      -Same-Day Home Discharge and Abciximab Bolus-Only compared to Overnight Hospitalization and Abciximab Bolus + Infusion after Trans-Radial Coronary Stenting. 12-Months Results by Dr. Oliver F. Bertrand

EPIC: Evaluation of 7E3 for the Prevention of Ischemic Complications

      -Abciximab for death, MI, and revascularization in percutaneous intervention

EPILOG: Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade

      -Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa receptor (abciximab) blockade

EPISTENT: EArly Discharge after Transradial Stenting of CoronarY Arteries

      -Same-Day Home Discharge and Abciximab Bolus-Only compared to Overnight Hospitalization and Abciximab Bolus + Infusion after Trans-Radial Coronary Stenting. 12-Months Results by Dr. Oliver F. Bertrand

GUSTO IV ACS: Global Use of Strategies To Open Occluded Coronary Arteries in ACS

      -Abciximab in NSTEMI/UA patients not planned to undergo PCI

INFUSE-AMI: A 2x2 Factorial, Multicenter, Prospective, Randomized Evaluation of Intracoronary Abciximab and Aspiration Thrombectomy in Patients Undergoing Primary PCI for Anterior STEMI.

      -Trial Overview by Dr. Gregg W. Stone (ACC 2012)

ISAR-REACT 2: The Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2

      -Abciximab Vs. Placebo in Patients with NSTEMI undergoing PCI Aftrer Pretreatment with Clopidogrel by Dr. M. Seyfarth

MULTI-STRATEGY Trial: MULTIcentre evaluation of Single high-dose bolus TiRofiban versus Abciximab with sirolimus eluting sTEnt or bare metal stent in acute myocardial infarction studY

      -Evaluation of single high-bolus dose tirofiban Vs. abciximab and SES Vs. BMS in acute MI by Dr. Marco Valgimigli

RELAx-AMI: Randomized Early versus Late AbciXimab in Acute Myocardial Infarction treated with primary coronary intervention

      -Early versus Late Abciximab in AMI treated with primary coronary intervention by Dr. Mauro Maioli

 

SCAAR: Non-randomized Comparison from SCAAR of Eptifibatide of Abciximab in Primary PCI for STEMI

      -Results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) by Dr. Axel Akerblom

TARGET: Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial

      -Safety and efficacy of tirofiban vs abciximab in the setting of percutaneous coronary revascularization

      -Six Month Results

(Return to Contents)

Aggrastat (Tirofiban) Slides

Summary

APEX: Assessment of Pexelizumab in Acute Myocardial Infarction

      -New Treatment Advances in Acute Coronary Syndrome

Case Studies in the Management of ACS with GP IIb/IIIa Inhibitors

      -Case Studies Presentation

Empiric Management of ACS with GP IIb/IIIa Platelet Receptor Blockers

      -Continuing Medical Education Activity by Drs. Christopher P. Cannon and Alan C. Yeung

MULTI-STRATEGY Trial: MULTIcentre evaluation of Single high-dose bolus TiRofiban versus Abciximab with sirolimus eluting sTEnt or bare metal stent in acute myocardial infarction studY

      -Study Design by Dr. Marco Valgimigli

STRATEGY Trial: sTEnt versus abciximab and bare metal stent in acute mYocardial infarction

      -Three-year clinical follow-up after sirolimus-eluting versus bare metal stent implantation assisted by systematic GP IIb/IIIa infusion in patients with MI by Dr. Marco Valgimigli

Tirofiban Meta-Analysis

      -30-Day Results by Dr. Marco Valgimigli

Understanding Concepts of Equivalence and Non-inferiority Trials

      -Understanding Concepts of Equivalence and Non-inferiority Trials by Dr. C. Michael Gibson



Trials

MULTI-STRATEGY Trial: MULTIcentre evaluation of Single high-dose bolus TiRofiban versus Abciximab with sirolimus eluting sTEnt or bare metal stent in acute myocardial infarction studY

      -Study Design by Dr. Marco Valgimigli

PRISM-Plus: The Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms

      -Tirofiban and heparin in the treatment of unstable angina and non-Q-wave myocardial infarction

PRISM/RESTORE

      -Effect of tirofiban in patients undergoing coronary interventions

TACTICS-TIMI 18: Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy

      -Economics and HRQOL

TOPSTAR: Effect of Additional Temporary Glycoprotein IIb-IIIa Receptor Inhibition on Troponin Release in Elective Percutaneous Coronary Interventions After Pretreatment With Aspirin and Clopidogrel

      -IIb/IIIa Inhibition on Top of Aspirin, Unfractionated Heparin, and Clopidogrel in Elective PCI Patients

(Return to Contents)

Eptifibatide (Integrilin) Slides

Summary

Safety and Efficacy of Adjusted-Dose Eptifibatide in Patients with Acute Coronary Syndromes and Reduced Renal Function:

      -Overview by Dr. Chiara Melloni


Trials

Early ACS: Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome

      -Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndromes

      -An Analysis from the Early ACS Trial by Dr. Tracy Wang (ACC 2010)

ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial

      -Stent Parameters Predict Major Adverse Clinical Events and the Response to Platelet Glycoprotein IIb/IIIa Blockade

 

SCAAR: Non-randomized Comparison from SCAAR of Eptifibatide of Abciximab in Primary PCI for STEMI

      -Results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) by Dr. Axel Akerblom

 

(Return to Contents)

Who Are We?    Slide Downloading Policy   Financial Disclosure    We Do Not Promote Off Label Product Use    Copyright    Source of Slides    Editorial Policy    Links Policy    Privacy Policy   Access    CME Programs

1999-2009 by Clinical Trial Results .org.  None of the materials on this website may be reproduced, modified, distributed, transmitted, republished, displayed, or performed unless prior written approval is obtained by Clinical Trial Results.  All such requests should be forwarded to Susan J. Marble at smarble@clinicaltrialresults.org. For further information please see the Policy section. Webmaster